VJOncology is committed to improving our service to you

ESMO 2019 | IMpower133: atezolizumab, carboplatin plus etoposide for SCLC

VJOncology is committed to improving our service to you

Martin Reck

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses the IMpower133 (NCT02763579) trial updated overall survival (OS) analysis of first-line atezolizumab plus carboplatin plus etoposide in extensive-stage small-cell lung cancer SCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter